+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Liver Fibrosis Drugs Market by Drug Class (Biologic Therapies, Cell Therapies, Gene Therapies), Mechanism Of Action (ASK1 Inhibitors, Galectin-3 Inhibitors, PPAR Agonists), Route Of Administration, Distribution Channel - Global Forecast 2025-2030- Product Image
Liver Fibrosis Drugs Market by Drug Class (Biologic Therapies, Cell Therapies, Gene Therapies), Mechanism Of Action (ASK1 Inhibitors, Galectin-3 Inhibitors, PPAR Agonists), Route Of Administration, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

Liver Fibrosis Drugs Market by Drug Class (Biologic Therapies, Cell Therapies, Gene Therapies), Mechanism Of Action (ASK1 Inhibitors, Galectin-3 Inhibitors, PPAR Agonists), Route Of Administration, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 196 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 4904956
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The liver fibrosis drugs market is experiencing transformative shifts propelled by therapeutic innovation, evolving regulatory landscapes, and the growing need for disease-modifying interventions. Stakeholders now face a complex environment that demands strategic vision and agile decision-making to capture emerging opportunities in this rapidly changing arena.

Market Snapshot: Liver Fibrosis Drugs Market Growth & Outlook

The Liver Fibrosis Drugs Market grew from USD 15.57 billion in 2024 to USD 17.12 billion in 2025. It is expected to continue growing at a CAGR of 9.87%, reaching USD 27.40 billion by 2030. Market expansion is being driven by increased emphasis on targeted therapies, accelerated regulatory approvals, and rising clinical needs. Industry participants increasingly leverage collaborative R&D, advanced supply chain strategies, and dynamic reimbursement models to maintain their competitive edge and ensure broader patient access.

Scope & Segmentation of the Liver Fibrosis Drugs Market

This report delivers an in-depth analysis of the liver fibrosis therapeutic landscape, covering strategic aspects of drug classes, mechanisms, delivery channels, and regional markets. Detailed segmentation offers actionable insights for investment, market entry, and R&D prioritization across the following dimensions:

  • Drug Class:
    • Biologic therapies, including monoclonal antibodies and recombinant proteins
    • Cell therapies
    • Gene therapies
    • Small molecule inhibitors from both natural products and synthetic compounds
  • Mechanism of Action:
    • ASK1 inhibitors
    • Galectin-3 inhibitors
    • PPAR agonists (alpha, delta, gamma types)
    • TGF beta blockers
  • Route of Administration:
    • Injectables (intravenous and subcutaneous)
    • Oral formulations
  • Distribution Channel:
    • Hospital pharmacy
    • Online pharmacy
    • Retail pharmacy—both chain and independent settings
  • Geographic Regions:
    • Americas: United States (California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio), Canada, Mexico, Brazil, Argentina
    • Europe, Middle East & Africa: United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland
    • Asia-Pacific: China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan
  • Key Industry Participants:
    • Gilead Sciences, AbbVie, Roche, Bristol-Myers Squibb, Pfizer, Novartis, Takeda, Merck, Intercept Pharmaceuticals, Madrigal Pharmaceuticals

Liver Fibrosis Drugs Market: Key Takeaways for Decision Makers

  • Therapeutic development is rapidly shifting from symptom management to disease-modifying and curative approaches, driven by biotechnology and genomics advances.
  • Collaboration models, including partnerships among large pharma, emerging biotechs, and contract manufacturing organizations, are accelerating innovation and enabling faster commercialization.
  • Patient-centric trial designs, real-world evidence integration, and adaptive protocols are streamlining regulatory processes and supporting stakeholder alignment with payer expectations.
  • Combination therapies are gaining traction, targeting multiple pathways to address the complex etiology of liver fibrosis for improved clinical outcomes.
  • Strategic supply chain adaptation and intelligent pricing structures help maintain product accessibility in response to shifting policy and market conditions.
  • Regional diversity in regulatory frameworks and healthcare infrastructure broadens the spectrum of market opportunities, requiring tailored entry and access strategies.

Tariff Impact: Navigating New Supply Chain and Pricing Realities

The introduction of targeted pharmaceutical tariffs in the United States in 2025 has prompted manufacturers to refine procurement and production strategies. There is intensified movement toward onshoring active pharmaceutical ingredient sourcing and establishing domestic partnerships to alleviate risk. These measures also impact resource allocation, cost structures, and compliance planning, requiring ongoing communication with stakeholders and payers.

Methodology & Data Sources

Analysis is grounded in a robust, multi-phase research framework. This includes peer-reviewed literature, regulatory submissions, patent databases, and metadata from trial registries. Insights are validated via structured interviews with clinical, regulatory, and commercial leaders, triangulated by qualitative workshops and expert panels to assure empirical integrity.

Why This Report Matters for Senior Leaders

  • Helps leadership anticipate scientific and policy trends that may reshape investment or M&A prioritization in the liver fibrosis therapeutics sector.
  • Provides actionable intelligence for developing resilient supply chains, market entry plans, and product differentiation in light of geographic and regulatory diversity.
  • Empowers executives to align innovation, access, and cost management through advanced segmentation strategies and technology deployment.

Conclusion

Senior decision-makers can leverage this report to understand and act on the evolving landscape in liver fibrosis drug development. Adaptive strategies, collaborative frameworks, and focus on patient-centricity will equip organizations to capitalize on emerging opportunities and navigate complexity with confidence.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emerging combination therapies targeting inflammation and fibrogenesis in liver fibrosis patients
5.2. Advances in noninvasive imaging biomarkers accelerating early detection of liver fibrosis progression
5.3. Stratified clinical trial designs leveraging genomic and metabolic biomarkers for patient selection in liver fibrosis drug development
5.4. Regulatory momentum behind accelerated approval pathways for novel antifibrotic agents in hepatic disease management
5.5. Strategic partnerships between biotech firms and academic centers driving discovery of next generation fibrogenesis inhibitors
5.6. Rising adoption of oral small molecule therapies over injectables in chronic liver fibrosis treatment regimens
5.7. Market access challenges influenced by high pricing strategies and evolving reimbursement policies for fibrosis drugs
5.8. Integration of digital health solutions enabling remote monitoring of treatment response in liver fibrosis therapies
5.9. Real world evidence from longitudinal disease registries shaping clinical guidelines and market penetration strategies
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Liver Fibrosis Drugs Market, by Drug Class
8.1. Introduction
8.2. Biologic Therapies
8.2.1. Monoclonal Antibodies
8.2.2. Recombinant Proteins
8.3. Cell Therapies
8.4. Gene Therapies
8.5. Small Molecule Inhibitors
8.5.1. Natural Products
8.5.2. Synthetic Compounds
9. Liver Fibrosis Drugs Market, by Mechanism Of Action
9.1. Introduction
9.2. ASK1 Inhibitors
9.3. Galectin-3 Inhibitors
9.4. PPAR Agonists
9.4.1. PPAR Alpha
9.4.2. PPAR Delta
9.4.3. PPAR Gamma
9.5. TGF Beta Blockers
10. Liver Fibrosis Drugs Market, by Route Of Administration
10.1. Introduction
10.2. Injectable
10.2.1. Intravenous
10.2.2. Subcutaneous
10.3. Oral
11. Liver Fibrosis Drugs Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
11.4.1. Chain Pharmacy
11.4.2. Independent Pharmacy
12. Americas Liver Fibrosis Drugs Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Liver Fibrosis Drugs Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Liver Fibrosis Drugs Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Gilead Sciences, Inc.
15.3.2. AbbVie Inc.
15.3.3. F. Hoffmann-La Roche Ltd.
15.3.4. Bristol-Myers Squibb Company
15.3.5. Pfizer Inc.
15.3.6. Novartis AG
15.3.7. Takeda Pharmaceutical Company Limited
15.3.8. Merck & Co., Inc.
15.3.9. Intercept Pharmaceuticals, Inc.
15.3.10. Madrigal Pharmaceuticals, Inc.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. LIVER FIBROSIS DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. LIVER FIBROSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. LIVER FIBROSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. LIVER FIBROSIS DRUGS MARKET: RESEARCHAI
FIGURE 24. LIVER FIBROSIS DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 25. LIVER FIBROSIS DRUGS MARKET: RESEARCHCONTACTS
FIGURE 26. LIVER FIBROSIS DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. LIVER FIBROSIS DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY CELL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY CELL THERAPIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GENE THERAPIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GENE THERAPIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY NATURAL PRODUCTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY NATURAL PRODUCTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SYNTHETIC COMPOUNDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SYNTHETIC COMPOUNDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ASK1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ASK1 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GALECTIN-3 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GALECTIN-3 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR ALPHA, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR ALPHA, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR DELTA, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR DELTA, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR GAMMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR GAMMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY TGF BETA BLOCKERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY TGF BETA BLOCKERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 115. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 116. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 117. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2024 (USD MILLION)
TABLE 118. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2025-2030 (USD MILLION)
TABLE 119. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 120. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 121. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 122. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 123. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2024 (USD MILLION)
TABLE 124. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2025-2030 (USD MILLION)
TABLE 125. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 126. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 127. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 128. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 129. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 130. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 131. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 132. CANADA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 133. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 134. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 135. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2024 (USD MILLION)
TABLE 136. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2025-2030 (USD MILLION)
TABLE 137. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 138. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 139. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 140. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 141. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2024 (USD MILLION)
TABLE 142. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2025-2030 (USD MILLION)
TABLE 143. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 144. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 145. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 146. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 147. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 148. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 149. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 150. MEXICO LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 151. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 152. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 153. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2024 (USD MILLION)
TABLE 154. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2025-2030 (USD MILLION)
TABLE 155. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 156. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 157. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 158. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 159. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2024 (USD MILLION)
TABLE 160. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2025-2030 (USD MILLION)
TABLE 161. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 162. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 163. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 164. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 165. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 166. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 167. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 168. BRAZIL LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 169. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 170. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 171. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2024 (USD MILLION)
TABLE 172. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2025-2030 (USD MILLION)
TABLE 173. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 174. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 175. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 176. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 177. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2024 (USD MILLION)
TABLE 178. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2025-2030 (USD MILLION)
TABLE 179. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 180. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 181. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 182. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 183. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 184. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 185. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 186. ARGENTINA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2024 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2025-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2024 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2025-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 207. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 208. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 209. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2024 (USD MILLION)
TABLE 210. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2025-2030 (USD MILLION)
TABLE 211. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 212. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 214. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2024 (USD MILLION)
TABLE 216. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2025-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 218. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 219. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 220. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 221. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 222. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 223. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 224. UNITED KINGDOM LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 225. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 226. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 227. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2024 (USD MILLION)
TABLE 228. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2025-2030 (USD MILLION)
TABLE 229. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 230. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 231. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 232. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 233. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2024 (USD MILLION)
TABLE 234. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2025-2030 (USD MILLION)
TABLE 235. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 236. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 237. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 238. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 239. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 240. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 241. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 242. GERMANY LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 243. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 244. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 245. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2024 (USD MILLION)
TABLE 246. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2025-2030 (USD MILLION)
TABLE 247. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 248. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 249. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 250. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 251. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2024 (USD MILLION)
TABLE 252. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2025-2030 (USD MILLION)
TABLE 253. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 254. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 255. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 256. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 257. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 258. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 259. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 260. FRANCE LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 261. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 262. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 263. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2024 (USD MILLION)
TABLE 264. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2025-2030 (USD MILLION)
TABLE 265. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 266. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 267. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 268. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 269. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2024 (USD MILLION)
TABLE 270. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2025-2030 (USD MILLION)
TABLE 271. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 272. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 273. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 274. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 275. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 276. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 277. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 278. RUSSIA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 279. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 280. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 281. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2024 (USD MILLION)
TABLE 282. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2025-2030 (USD MILLION)
TABLE 283. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 284. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 285. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 286. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 287. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2024 (USD MILLION)
TABLE 288. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2025-2030 (USD MILLION)
TABLE 289. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 290. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 291. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 292. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 293. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 294. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 295. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 296. ITALY LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 297. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 298. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 299. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2024 (USD MILLION)
TABLE 300. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2025-2030 (USD MILLION)
TABLE 301. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 302. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 303. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 304. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 305. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2024 (USD MILLION)
TABLE 306. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2025-2030 (USD MILLION)
TABLE 307. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 308. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 309. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 310. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 311. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 312. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 313. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 314. SPAIN LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 315. UNITED ARAB EMIRATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 316. UNITED ARAB EMIRATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 317. UNITED ARAB EMIRATES LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2024 (USD MILLION)
TABLE 318. UNITED ARAB EMIRATES LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2025-2030 (USD MILLION)
TABLE 319. UNITED ARAB EMIRATES LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 320. UNITED ARAB EMIRATES LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 321. UNITED ARAB EMIRATES LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 322. UNITED ARAB EMIRATES LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 323. UNITED ARAB EMIRATES LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2024 (USD MILLION)
TABLE 324. UNITED ARAB EMIRATES LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONIST

Samples

Loading
LOADING...

Companies Mentioned

  • Gilead Sciences, Inc.
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • Novartis AG
  • Takeda Pharmaceutical Company Limited
  • Merck & Co., Inc.
  • Intercept Pharmaceuticals, Inc.
  • Madrigal Pharmaceuticals, Inc.

Table Information

Report AttributeDetails
No. of Pages196
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 17.12 Billion
Forecasted Market Value ( USD ) by 2030 $ 27.4 Billion
Compound Annual Growth Rate9.8%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Liver Fibrosis Market - Product Image

Liver Fibrosis Market

  • Report
  • 250 Pages
  • Global
From
Liver Fibrosis- Pipeline Insight, 2025 - Product Image

Liver Fibrosis- Pipeline Insight, 2025

  • Drug Pipelines
  • 85 Pages
  • Global
From
Liver Fibrosis Drug Pipeline Analysis Report 2025 - Product Image

Liver Fibrosis Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • 200 Pages
  • Global
From
Non-Alcoholic Steatohepatitis (NASH) - Pipeline Insight, 2025 - Product Image

Non-Alcoholic Steatohepatitis (NASH) - Pipeline Insight, 2025

  • Clinical Trials
  • 240 Pages
  • Global
From
Liver Fibrosis Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Liver Fibrosis Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 185 Pages
  • Global
From

About the Liver Fibrosis Drug Market

The Liver Fibrosis Drug market is a subset of the pharmaceutical industry focused on the development of treatments for liver fibrosis. Clinical trials are a key component of the development process, as they provide evidence of the safety and efficacy of a drug. Clinical trials are conducted in phases, with each phase providing increasingly detailed information about the drug's effects. The first phase of a clinical trial typically involves a small number of participants and is designed to assess the safety of the drug. Subsequent phases involve larger numbers of participants and are designed to assess the efficacy of the drug. The Liver Fibrosis Drug market is highly competitive, with many companies vying for a share of the market. Companies in the market include Gilead Sciences, Merck, Novartis, Pfizer, and Roche. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.